Navigation Links
Accera, Inc. Announces Open-Label Data from Phase II Study in,Alzheimer's Disease at International Conference on Prevention of,Dementia

BROOMFIELD, Colo., June 11, 2007 /PRNewswire/ -- Accera, Inc. today is presenting data from an open-label extension of its Phase IIb clinical trial of AC-1202 (Ketasyn) in Alzheimer's disease (AD) at the Alzheimer's Association's International Conference on Prevention of Dementia in Washington, D.C. Consistent with the findings of earlier clinical and preclinical studies, AC-1202 was shown to be safe and to significantly improve the memory and cognition of subjects of a particular pharmacogenomic profile.

The randomized, double-blinded, placebo-controlled Phase IIb trial evaluated 152 subjects that had previously been diagnosed with mild to moderate AD at 25 centers across the United States. AC-1202 was administered once daily, and most patients continued to take their other AD drugs such as acetylcholinesterase inhibitors. Following three months of treatment and a two-week washout, eligible subjects were given the opportunity to receive AC- 1202 in a six-month open-label extension study. The main clinical outcome for efficacy was improvement in the AD Assessment Scale-Cognitive (ADAS-Cog) score, which measures memory and other aspects of cognitive performance.

In the double-blind phase of the clinical study the ADAS-Cog scores of the AC-1202-treated ApoE4(-) population improved 3.5 points in twelve weeks (p=0.01) compared to the placebo group, and statistically significant improvement was seen in just 45 days. ApoE4(-) subjects who also exhibited a genetic variation that affects glucose regulation showed a 5-point improvement in ADAS-Cog scores compared to placebo, providing further insight into the disease.

As in the double-blind phase of the study, the most profound effect was seen in subjects not expressing the ApoE4 genotype, a genetic risk factor for AD. ApoE4(-) subjects represent the other half of Alzheimer's patients. ApoE4(-) subjects who started taking AC-1202 on the open-label e
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Accera, Inc. Announces Results of Phase II Study in Alzheimers Disease at American Academy of Neurology Meeting
2. Accera, Inc. to Present Results of Phase II Study in Alzheimers Disease at American Academy of Neurology Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
(Date:1/15/2014)... 2014 Tegra Medical is very pleased to announce the ... new Chief Executive Officer.  Mark was promoted from his current ... the company,s four facilities in Massachusetts , ... joined Tegra Medical in 2012 with 20+ years of broad-based ...
(Date:1/15/2014)... PHILADELPHIA , Jan. 15, 2014  Echo Therapeutics, Inc. ... company developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and Interim CEO ... Capital Markets, Tenth Annual Equity Conference. ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
(Date:4/24/2014)... Nancy Chiaravalloti, PhD, of Kessler Foundation was named the ... City, New Jersey. Dr. Chiaravalloti spoke on April 24, ... topic of "Treating Cognitive Deficits Following Neurological Illness and ... a part of the long legacy of the Mendel ... "The field of rehabilitation research is a rewarding one. ...
(Date:4/24/2014)... at UT Southwestern Medical Center previously discovered that the ... adult heart lacks this ability. New research by the ... its incredible regenerative capability in adulthood, and the answer ... It is well-known that a major function of the ... But at the same time, oxygen is a highly ...
(Date:4/24/2014)... for BrainHealth will bring together national experts to ... at its inaugural Brain Health Summit, titled "The ... will include Dr. Sandra Bond Chapman, founder and ... Senator Chuck Grassley (R-IA), U.S. Representative Chaka Fattah ... Policy and Early Learning, U.S. Department of Education. ...
(Date:4/24/2014)... one out of three survivors of critical illness, ... The Lancet Respiratory Medicine , and the majority ... mentally. , It is one of the largest ... outcomes of critical care survivors, according to lead ... and it highlights a significant public health issue, ...
(Date:4/24/2014)... National Science Foundation has awarded LSU Health Sciences ... (REU) Site grant in the amount of $295,635. ... from diverse social and educational backgrounds, underrepresented in ... The project will provide students with training ... It will be led by Principal Investigator ...
Breaking Medicine News(10 mins):Health News:Kessler Foundation scientist named 63rd Mendel Lecturer by St. Peter's University 2Health News:Oxygen diminishes the heart's ability to regenerate, researchers discover 2Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3
... 20 proteins in the Wnt family are some of ... develops and grows, but for 30 years scientists have ... The proteins have eluded standard visualization techniques, in large ... water-based liquids normally used for biochemical studies. But once ...
... Institutes of Health (NIH) has awarded researchers at Albert ... $5.9 million grant to develop a new vaccine against tuberculosis ... multi drug-resistant and extensively drug-resistant. The grant will build on ... is based on genetically altered Mycobacterium smegmatis , which ...
... way to talk to someone about prognosis and quality of ... one had studied that question through direct observation, until the ... , The data is published online in the Journal ... E. Gramling, M.D., Sc.D., associate professor of Family Medicine at ...
... HealthDay Reporter , WEDNESDAY, May 30 (HealthDay News) -- How old ... humans possess the ability to judge whether a person has reached ... in the study correctly gauged whether the former wearer of an ... for the record, most didn,t think "old-people smell" was off-putting at ...
... Storrs HealthDay Reporter , WEDNESDAY, May 30 (HealthDay ... well as babies drinking cow,s milk formula on tests of ... study finds. But breast-fed babies score slightly higher than infants ... 20 percent of formula-fed babies in the United States are ...
... FORT KNOX, Ky., May 30, 2012 Last month, ... around the country attended the American College of Physicians, ... national medical student abstract competitions and share their perspective ... residents earned national awards for their research. "The ...
Cached Medicine News:Health News:New molecular structure offers first picture of a protein family vital to human health 2Health News:New molecular structure offers first picture of a protein family vital to human health 3Health News:Einstein awarded $6 million grant to develop new TB vaccine against drug-resistant strains 2Health News:Einstein awarded $6 million grant to develop new TB vaccine against drug-resistant strains 3Health News:Listening in, researchers learn about end-of-life communication 2Health News:Listening in, researchers learn about end-of-life communication 3Health News:Humans Can Sniff Out Old Age in Others, Study Shows 2Health News:Humans Can Sniff Out Old Age in Others, Study Shows 3Health News:Infant 'Smarts' Similar With Different Types of Formula: Study 2Health News:Infant 'Smarts' Similar With Different Types of Formula: Study 3Health News:Infant 'Smarts' Similar With Different Types of Formula: Study 4Health News:US Army internal medicine residents receive awards from American College of Physicians 2
Headlight module is mounted on UltraLite Plus sweatband....
... rapid rise in intracranial ... intervention and continuous monitoring. ... technology that gets to ... Its versatility makes it ...
... The CODMAN ICP Monitoring ... measurements of intracranial pressure ... or intraventricular levels. The ... rather than through a ...
... The Polaris system delivers the ... cost effective and easy to use, ... level of precision measurement with unprecedented ... both active and passive tools, the ...
Medicine Products: